Introduction
Peroxisomes are essential for -oxidation of very long chain fatty acids (VLCFA) and -oxidation of branched chain fatty acids (1) . However, peroxisomal fatty acid oxidation is incomplete, requiring chainshortened fatty acyl-CoAs to be shuttled out of peroxisomes and into mitochondria for complete oxidation.
Peroxisomes are also required for anabolic lipid metabolism, including the synthesis of ether lipids and some polyunsaturated fatty acids (PUFA). The endogenous synthesis of docosapentaenoic acid (22:56) and docosahexaenoic acid (C22:63, DHA) begins with the essential fatty acids linoleate (9,12-18:2) and linolenate (9,12,15-18: 3), respectively (2) . Due to the limited types of desaturases in mammals (5, 6 and 9), elongation and desaturation in the endoplasmic reticulum generates 6,9,12,15,18,21-24:6 and 6,9,12,15,18-24:5, both of which must be transported into peroxisomes and undergo one round of -oxidation to yield 22 carbon PUFAs (1, 3) . A second round of peroxisomal oxidation of yields arachidonic acid (20:46, AA) and eicosapentanoic acid (20:53), but it is important to note that peroxisomal oxidation is not essential for the synthesis of these lipids.
The entry of fatty acids into peroxisomes is thought to be dependent upon their esterification by a peroxisomal acyl-CoA synthetase followed by their transmembrane transport by members of the D-subfamily of ABC transporters (4, 5) . Among the four members of this subfamily, only ABCD1 (D1) has been associated with human disease, X-linked adrenoleukodystrophy (ALD). ALD is a pleiotropic disorder characterized by the accumulation of VLCFAs in plasma and tissues that presents with varying neurological, adrenocortical and Leydig cell deficiencies (6, 7) . The closest paralog of D1 is D2, which shares greater than 60% amino acid identity in both humans and mice and at least some overlapping function in vitro and in vivo (8) (9) (10) (11) (12) . While direct evidence for transmembrane transport of fatty acyl-CoA substrates is still lacking, human D1 and D2 transgenes have been shown to rescue growth in oleate containing media and promote the oxidation of distinct subsets of fatty acids in yeast lacking endogenous peroxisomal fatty acyl-CoA transporters (13, 14) . In this system, D2 was most active towards the 22-carbon saturated fatty acid and 22-and 24-carbon PUFAs (14) .
Whereas D1 is constitutively expressed in many tissues, D2 is more restricted and dynamically regulated by transcription factors involved in lipogenesis, fatty acid oxidation and cholesterol elimination. D2 mRNA and by guest, on November 9, 2017 www.jlr.org
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Page 4 of 23 protein have been detected in brain, liver, lung, adrenal gland, and skeletal muscle, but are most abundant in adipose tissue (9, 15) . Within adipose, D2 is restricted to adipocytes and is upregulated during adipogenesis, presumably by the lipogenic transcription factor, sterol receptor element binding protein 1(SREBP1) (15, 16) .
Conversely, the expression of D2 is relatively low in liver, but is upregulated by fasting and peroxisome proliferator activated receptor (PPAR)  agonists (9) . Interestingly, hepatic expression of D2 is suppressed by the liver X receptor (LXR), suggesting a role for D2 in cholesterol metabolism (16) . However, the functional significance of this observation is unclear and has not been investigated.
Despite its regulation by transcriptional factors essential for lipid homeostasis in both liver and adipose, the physiological role for D2 in lipid metabolism remains largely unknown. The absence of D2 results in a modest accumulation of VLCFAs in liver following feeding with a diet enriched in saturated fat and after prolonged fasting, but these differences did not result in overt metabolic phenotypes nor did they affect the expression of key metabolic enzymes (12) . Similarly, there is no apparent adipose dysfunction and fatty acid profiles in adipose tissue were largely unaffected in D2 deficient mice (15) . As in liver, adrenal and neural tissues, there was a modest accumulation of 22-and 24-carbon saturated (SFA) and monounsaturated fatty acids (MUFA). When acutely challenged with a diet enriched in erucic acid (22:1-9), there was a gene-dosage dependent increase in the levels in adipose and plasma (15) .
Erucic Acid (EA) is abundant in native cultivars of rapeseed (Brassica napus) and is used clinically in combination with oleic acid to reduce plasma levels of VLCFA in patients with ALD due to its ability to inhibit the elongation of SFAs (6) . However, it is also associated with a transient lipidosis, dyslipidemia and the development of dilated cardiomyopathy in rats, effects not observed in mice and opposed by treatment with the PPAR agonist, clofibrate (17) .
We hypothesized that the absence of D2 would sensitize mice to disturbances in lipid metabolism by dietary EA. Our results indicate that in the absence of D2, dietary EA promotes obesity, insulin resistance and steatosis. However, the absence of D2 had no impact on the development of obesity phenotypes when challenged with a high-fat diet or when crossed with leptin-deficient (ob/ob) mice. Although adipose tissue is greatly by guest, on November 9, 2017 www.jlr.org
Page 5 of 23 expanded following erucic acid feeding, the lipid profile is only marginally affected with little accumulation of EA. While there is a significant increase in EA in liver, it constitutes less than 2% of the total fatty acid pool.
Conversely, hepatic SFA and MUFA content are elevated by two-and three-fold, respectively. These data suggest that in the absence of D2, peroxisomal metabolism of EA proceeds efficiently in the liver, but that EA metabolites disrupt hepatic lipid metabolism, resulting in obesity, insulin resistance and steatosis.
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Experimental Procedures
Animal husbandry Mice harboring the mutant Abcd2 allele are maintained on the C57BL/6J background as heterozygotes. Strain refreshing is conducted every five generations using C57BL6/J females obtained from The Jackson Laboratory (Bar Harbor, ME). Genotyping experiments to differentiate Abcd2-deficient (D2 KO) from heterozygous and wild-type mice were conducted as previously described (18) . Animals were housed in individually ventilated cages in a temperature-controlled room with 14:10 light:dark cycle and provided with enrichment in the form of acrylic huts and nesting material. All mice were maintained on standard rodent chow (Harlan Teklad 2014S) until initiation of experiments. All animal procedures conform to PHS policies for humane care and use of laboratory animals and were approved by the institutional animal care and use committee at the University of Kentucky.
The erucic acid enriched diet was custom formulated to contain levels of EA found in native rapeseed oil and contained 21.6% total energy from fat (Research Diets, New Brunswick, NJ, Tables S1 and S2). Erucic acid accounted for 55.6% of total fatty acids as determined by GC-MS. The diet was stored at 4 o C, provided ad libitum and replaced twice weekly to limit oxidation. Diets were initiated at 8 weeks of age and continued until termination of the experiment following 8 weeks of feeding (n=7 Histology Tissue was processed in a dehydrating ethanol gradient, followed by xylene incubation and paraffin embedding. Paraffin blocks of tissue were cut into sections of 1-3 m thickness and stained for haematoxylin and eosin (H&E). Frozen sections were cut at 10m thickness and subjected to Oil-Red-O staining.
Lipid Analysis Total lipids from liver and adipose were analyzed as previously described (15) . Hepatic cholesterol and triglycerides were determined using enzymatic, colorometric assays. For GC/MS, total lipid extracts were saponified and esterified with 10% boron trifluoride in methanol (BF3-methanol 10%, Supelco, Bellefonte, PA). BF 3 and methanol were removed and samples were injected into a gas chromatography system (Agilent 6890 GC G2579A system, Palo Alto, CA) equipped with a split injection system with parallel OMEGAWAX TM 250 capillary columns (Supelco, Bellefonte, PA) and either an FID detector (quantitative) or Agilent 5973 network mass selective detector (target identity). The GC program was: Injector: 1µl at 10:1 spilit, 250°C; Detector: FID, 260°C; oven: 160°C (5min) to 220°C at 4C/min; Carrier: helium, 1.2 ml/min. Hepatic levels of diacylglycerol and ceramide were determined as previously described (19, 20) .
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The acyl-carnitine extraction method is a modification of the method previously described (21) . Tissues were weighed and homogenized in water and extracted with 80 % acetonitrile with a series of vortexing, sonication and centrifugation at 4000 rpm for 10 min. Supernatant was transferred into a vial and dried under nitrogen, which was finally reconstituted with 100 uL of methanol. D3-C2, D3-C4 and D3-C16 acylcarnitines were used as internal standards for short and long chain acyl carnitines respectively. Analyses of acylcarnitines was carried out using a Shimadzu UFLC coupled with an AB Sciex 4000-Qtrap hybrid linear ion trap triple quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode. Acyl carnitines were analyzed using an XTerra MS Enzyme Assays Fatty acid elongation was determined as described previously (22) . Briefly, microsomes (30 Protein and RNA Analysis Membrane proteins were prepared and analyzed by SDS-PAGE and immunoblot analysis as previously described (25) . The isolation of total RNA and the determination of relative transcript abundance by quantitative Real-Time PCR (qRT-PCR) for both tissues and cells was conducted as previously described (25) .
Statistical Analysis Body composition data were analyzed by two-way repeated measures ANOVA.
Bonferroni posts tests were employed where indicated. Comparisons between genotypes for other measures were conducted with two-tailed t-tests. All statistical analyses were conducted using GraphPad Prism statistical analysis software.
Results D2 deficient mice are susceptible to EA-induced obesity, dyslipidemia and loss of glycemic control.
To determine the role of D2 in the metabolism of dietary EA, mice were challenged with an EA-enriched enriched diet for 8 weeks beginning at 8 weeks of age. As previously reported, differences in body weight, body composition and other measures of obesity and lipid metabolism were not observed at the initiation of the study ((15), Figure 1) . Following EA feeding, we observed a modest, but significant increase in body weight in D2 KO mice compared to wild-type controls. Analysis of body composition by MRI indicated a significant increase in fat mass in D2 KO mice after 8 weeks on diet. The accumulation of excess adipose tissue occurred primarily in epididymal and retroperitoneal depots ( Figure 1B ). Whereas lean mass increased in wild-type mice during EA feeding, it remained relatively constant in D2 KO and was significantly lower than in wild-type controls at the termination of the study ( Figure 1A ). The expansion of adipose mass in the absence of an increase in lean mass resulted in a substantial increase in adiposity in D2 KO mice ( Figure 1C ). Histological analysis of epididymal fat
indicates that the expansion of adipose tissue was associated with the enlargement of adipocytes ( Figure 1D ).
Fasting glucose levels were increased in D2 KO mice compared to wild-type controls ( Figure 1E) . A glucose tolerance test conducted after seven weeks on diet revealed a decrease in glucose disposal consistent with the development of insulin resistance ( Figure 1F&G ). Whereas fasting levels of triglycerides were unaffected, serum cholesterol was significantly elevated ( Table 1 ).
The expansion of adipose and the loss of glycemic control are generally associated with adipose tissue inflammation. Consistent with the expansion of adipose tissue, leptin levels were elevated in D2 KO mice (Table   1 ). However, we failed to detect any differences in other adipocytokines typically associated with inflammation.
We also stained adipose tissue sections for CD68 and did not observe an accumulation of macrophages or the presence of crown-like structures (data not shown). These data suggest the absence of inflammation in D2 KO adipose tissue following EA feeding despite the increase in adipose mass and adipocyte hypertrophy.
D2 does not influence the development of diet-induced obesity
Page 11 of 23 D2 is upregulated in liver of obese and insulin resistant mice, suggesting that D2 might modulate the development of obesity phenotypes in multiple mouse models (26)( Figure S1 ). First, mice were challenged with a high fat (45% kCal) diet for 12 weeks beginning at 8 weeks of age ( Figure 2) . Although there was a modest increase in fat mass, we observed no differences in body weight, adiposity, fasting glucose or glucose tolerance.
There were also no differences in food intake or blood lipids (Table S3) . We next crossed D2 deficient mice with the leptin deficient (ob/ob) strain, maintained them on standard rodent chow and evaluated them at 8, 12 and 16 weeks of age. As in high fat feeding, there was a tendency towards increased fat mass at 12 weeks, but no differences in other measures of obesity phenotypes ( Figure S2 , Table S3 ).
Dietary EA alters adipose fatty acid profile and gene expression
GC-MS analysis of the fatty acid profile in epididymal adipose showed that the relative abundance of EA was similar in wild-type and D2 KO mice and comprised less than 7% of the total fatty acids within adipose tissue However, it should be noted that given the increase in adipose tissue mass, the total amount of all fatty acids within adipose is greater in D2 KO than wild-type mice. On the whole, there was an increase in SFA and a decrease in MUFA in adipose tissue, while the levels of PUFA were unaffected (Figure 3, inset) . These data are consistent with previous reports indicating that EA is not a preferred substrate for TG synthesis in adipose tissue (27) .
To explore potential mechanisms for increased adiposity, we analyzed mRNA levels of key genes involved in the regulation of adipose function and lipid and carbohydrate metabolism. Insulin-induced gene-1 (INSIG1), but not INSIG2 was downregulated in D2 KO mice. Although the expression of SREBP1 was not altered, several SREBP1 target genes were downregulated in adipose tissue of D2 KO mice fed EA including: Acetyl-CoA carboxylase (ACC1), fatty acid synthase (FAS) and stearoyl CoA-desaturase (SCD1) ( Figure 3B ). There was also a 2.5-fold increase in the expression of D1 in adipose of D2 KO mice fed erucic acid, but it should be noted that by guest, on November 9, 2017 www.jlr.org D1 expression in adipose is near the limit of detection in adipocytes (15) . Transcription factors that regulate cholesterol, fatty acid and glucose homeostasis were downregulated in D2 KO mice (LXR, ChREBP, Figure S3 ).
These data are largely consistent with the development of insulin resistance in adipose tissue associated with adipocyte hypertrophy, suggesting these changes are reflective of the development of the obesity and insulin resistance rather than mechanisms for EA-dependent phenotypes in D2 KO mice.
EA promotes hepatic steatosis in D2-deficient mice
The development of obesity and adipose insulin resistance is associated with ectopic lipid accumulation.
H&E staining of liver sections revealed vacuolar structures that stained positively with Oil-Red-O in D2 KO mice ( Figure 4 ). Hepatic triglycerides and cholesterol were elevated in the D2 KO mice compared to controls.
Whereas the alteration in the fatty acid profile in adipose tissue was limited to a few specific fatty acids, the hepatic fatty acid profile revealed significant differences for many fatty acid species. There is dramatic shift from wild-type to D2 KO mice toward more MUFA (C18-22) and less PUFA (C18-22, Figure 4E ). The relative levels of DHA and AA, key inhibitors of hepatic lipogenesis that suppress SREBP1 processing and transcriptional activity, are significantly reduced.
EA is an inhibitor of fatty acid elongation, an essential step in PUFA synthesis (28) . The deletion of fatty acid elongase 5 (ELOVL5) reduces hepatic levels of DHA and AA and promotes steatosis in mice (22) .
Therefore we measured elongation of several ELOVL5 substrates to determine if EA reduced the activity of this enzyme in D2 KO mice ( Figure 5 ). Rather than a reduction in ELOVL5 activity, the elongation of intermediates of PUFA synthesis was significantly elevated. We next measured the abundance of mRNAs for lipogenic genes ( Figure 5B ). While mRNA for SREBP1 was elevated, we did not observe significant increases in key lipogenic genes including ACC1 and FAS. There was a modest, but significant increase in SCD1 mRNA, but there was no increase in enzyme activity ( Figure 5C ). These data indicate that hepatic steatosis is unrelated to the relative reduction in PUFAs and disinhibition of hepatic SREBP1 processing and activity. Unlike adipose, there was no increase in hepatic expression of D1 in D2 KO liver. The accumulation of diacylglycerol and ceramide are associated with the development of steatosis and the progression of NAFLD (29) . Total diacylglycerols and ceramides appear to be elevated in hepatic lipid extracts from D2 KO mice. However, the levels were quite variable and these differences did not reach statistical significance ( Figure S5 ).
In contrast to adipose where tissue mass is comprised almost exclusively of TGs, liver fatty acid profiles differ substantially from fatty acid content. When reported on a per gram tissue basis, the fatty acids that accumulate in liver are limited to EA and its chain-shortened products of peroxisomal metabolism (20:1, 18:1 and 16:1, Figure 6C ). There is also an increase in 14-18 carbon SFA. Consequently, there is an accumulation of both SFA and MUFA in the absence of any change in PUFA ( Figure 6C , inset). Additional analysis of gene expression in liver revealed reductions in UCP2 and malic enzyme, but no alterations in the expression of transcriptional regulators of sterol and carbohydrate metabolism or fatty acid modifying enzymes ( Figure S4 ).
Collectively, the data suggest that the increase in hepatic MUFA is a consequence of peroxisomal shortening of EA. The increase in SFA does not appear to be a consequence of elevated lipogenesis and is more likely due to substrate competition for incorporation into secreted lipoproteins and mitochondrial oxidation. 
Discussion
The present study reveals a novel role for D2 in opposing disturbances in lipid metabolism associated with dietary EA. EA causes a transient lipidosis and dilated cardiomyopathy in several species and is associated with an elevation in hepatic triglycerides after long term feeding in rats (30) . However, mice are resistant to these effects. While the absence of D2 sensitizes mice to EA feeding, the phenotype differs substantially from rats. We did not observe hypertriglyceridemia in the present study or in previous studies with an acute challenge (15) . We also saw no evidence of cardiomyopathy. None-the-less, dietary EA resulted in a robust disruption of lipid metabolism leading to an expansion of adipose tissue, the loss of glycemic control and steatosis. This suggests that mice have sufficient D2 present at all times or can rapidly upregulate D2 to compensate for the presence of EA in the diet.
D2 is an SREBP1 target gene and is upregulated during adipogenesis, suggesting that D2-dependent peroxisomal metabolism may play an essential role in lipogenesis and TG storage. Indeed, an alternative pathway involving peroxisomal dihydroxyacetone phosphate acyltransferase accounts for approximately forty percent of TG synthesis in 3T3-L1 cells (31) . While D2 may supply this pathway with fatty acyl-CoAs, the absence of D2
did not reduce lipid accumulation in mouse embryonic fibroblasts differentiated into adipocytes (15) . Likewise, we observed no reduction in adipose mass in mouse models of diet-induced obesity regardless of whether adipose expansion was driven by excess dietary fat or by hyperphagia and lipogenesis. Consequently, the functional significance of SREBP1 regulated D2 expression remains unclear.
Although D2 opposes the accumulation of EA in adipose tissue and plasma following an acute dietary challenge (15) , EA levels in wild-type and D2 KO mice did not differ after eight weeks of EA feeding. Despite the fact that EA constituted 50% of the dietary fatty acid species, it accounts for only 5% of the fatty acids in adipose and did not differ between genotypes. This is in keeping with previous reports indicating that EA is a poor substrate for esterification and storage as TG and suggests that EA incorporation into adipose TGs reaches its maximum irrespective of the presence or absence of D2 (27) . In the presence of D2, EA is likely shortened to As in adipose tissue, the levels of EA are quite low in the liver and constitute less than 2% of the fatty acid profile. However, there is a significant increase in EA in D2 KO mice as well as 16-, 18-and 20-carbon MUFAs.
The relatively small amount of hepatic EA and the accumulation of its chain-shortened metabolites suggest EA is metabolized by peroxisomes in the liver. Opposite to adipose tissue, the liver expresses relatively low levels of D2 and high levels of D1 (9, 15) . D1 is the closest family member to D2 and while the transporters have distinct substrate spectra there is significant overlap, including EA. D1 expression was increased in adipose of D2 KO mice fed EA, but unchanged in liver. This transporter may therefore compensate for the absence of D2 with respect to EA metabolism. While the compensatory pathway prevents the accumulation of EA, it fails to prevent its disruptive effects on lipid metabolism.
The synthesis of 20-and 22-carbon PUFAs requires the activity of fatty acid elongases. In the absence of ELOVL5, mice develop steatosis due to PUFA deficiency (22) . EA inhibits fatty acid elongation and is used clinically to reduce VLCFAs in ALD patients, suggesting this could be a mechanism for EA-mediated disruptions in lipid metabolism in the absence of D2. Indeed, there is a relative reduction in hepatic PUFAs, including DHA and AA in D2 KO mice (Figure 4 ). However, fatty acid elongase activity was elevated in microsomes isolated from D2 KO mice. This increase in activity also appears to be the case in vivo based on the increase in 20:33, the product of 18:33 elongation. Consequently, the relative decline in PUFAs in the fatty acid profile may be misleading. There was no reduction in the absolute levels of PUFAs in the liver of D2 KO mice (Figure 6 ), but whether the absolute or relative levels of PUFAs is critical to feedback inhibition of lipogenesis is not known.
The expression of lipogenic genes was largely unaffected and there was no increase in the activity of SCD1, an essential enzyme for TG storage. These data suggest that hepatic PUFA content rather than relative levels are important for regulation of SREBP1 activity in vivo.
A surprising observation is that expansion of the adipose tissue and loss of glycemic control was not associated with the accumulation of inflammatory cytokines in plasma. Similarly, there was no evidence for by guest, on November 9, 2017 www.jlr.org Downloaded from macrophage infiltration and the formation of crown-like structures in adipose tissue. One potential explanation is that the feeding period for the present experiment was only 8 weeks. Perhaps with increased time, these hallmarks of obesity and insulin resistance would have presented. Regardless, the data indicate that adipose dysfunction and inflammation was not causative in the EA-dependent phenotype in D2 KO mice.
The role of peroxisomal metabolism in the development of obesity phenotypes is poorly understood, but may play a significant role. A recent study indicates that D2 expression and hepatic peroxisomal metabolism are increased during the development of obesity and insulin resistance in high-fat fed mice (26) . The products of peroxisomal metabolism include acylcarnitines that are capable of bypassing carnitine palmitoyltransferase 1 for entry into mitochondria irrespective of cellular levels of malonyl-CoA. High fat feeding and excess caloric intake result in mitochondrial overload, incomplete -oxidation and the accumulation of medium-chain acylcarnitines in the plasma of rodents (32) . Therefore, peroxisomal -oxidation could potentially contribute to mitochondrial overload and promote obesity phenotypes following high fat feeding. We measured acylcarnitines in liver of wild-type and D2 KO mice, but did not observe differences in individual acylcarnitines or the sums of short, medium or long-chain species ( Figure S6 ).
Conversely, there is an increase in peroxisomal lipid metabolism in mice resistant (A/J) to obesity and steatosis following high fat feeding, suggesting that peroxisomes may play a protective role with respect to the development of obesity phenotypes (33) . We have confirmed an increase in hepatic expression of D2 following high-fat feeding and have also observed an increase in ob/ob mice ( Figure S1 ). However, the absence of D2 played neither a protective nor deleterious role in the development of obesity phenotypes in mouse models of obesity and insulin resistance. While there may be a role for peroxisomes in the development of obesity and steatosis, it is independent of the presence or absence of D2 unless mice are challenged with a diet containing EA and perhaps other fatty acids that require peroxisomal metabolism prior to storage in TG pools.
The key finding from this study is that D2 opposes disturbances in lipid metabolism caused by dietary EA.
The abundance of D2 in adipose tissue is 50-fold higher than in liver, suggesting that metabolism of EA allows for its incorporation into TG within adipose tissue. In the absence of D2, EA is metabolized to its chain-shortened 
